依达拉奉联合重组组织型纤溶酶原激活剂治疗脑梗死的临床研究  

Efficacy of Edaravone and Recombinant Tissue-Type Plasminogen Activator on Patients with Cerebral Infarction

作　　者：覃星悦[1] 肖海[1] 樊金莲[1] 农媛[1] 张泰鹏[1] 

机构地区：[1]广西医科大学第八附属医院/贵港市人民医院神经内科,广西贵港537100

出　　处：《现代生物医学进展》2016年第33期6553-6555,6582,共4页Progress in Modern Biomedicine

摘　　要：目的：探究依达拉奉联合重组组织型纤溶酶原激活剂（rt-PA）对脑梗死（CI）患者的疗效影响。方法：选取于2013年5月-2015年10月期间我院收治的CI患者88例,随机分为对照组和观察组各44例,对照组给予依达拉奉治疗,观察组在对照组的基础上予以rt-PA溶栓治疗,观察两组治疗后的美国国立卫生院神经功能缺损评分（NIHSS）、疗效及血清肿瘤坏死因子-α（TNF-α）和白介素-6（IL-6）、白介素-12（IL-12）水平的变化。结果：两组治疗后NIHSS评分均较治疗前显著下降,且观察组较对照组下降更加显著,差异有统计学意义（P〈0.05）;观察组总有效率为77.27%,明显高于对照组的50.00%,差异有统计学意义（P〈0.05）,且两组患者在治疗过程中均未出现严重的不良反应。两组治疗后血清炎性因子水平均显著降低,差异具有统计学意义（P〈0.05）,且观察组改善程度均明显优于对照组,差异具有统计学意义（P〈0.05）。结论：依达拉奉联合rt-PA能显著减轻CI患者的炎症反应,改善神经功能缺损程度,值得临床推广。Objective： To investigate the therapeutic efficacy of edaravone combined with recombinant tissue-type plasminogen activator（rt-PA） on patients with cerebral infarction（CI）. Methods： A total of 88 cases of patients with CI in our hospital during May 2013 to October 2015 were randomly divided into observation group and control group with 44 cases in each group. The control group was treated with edaravone, the observation group was given rt-PA and thrombolytic therapy on the basis of control group. After treatment, the National Institutes of Health Stroke Scale（NIHSS）, curative effect and changes of serum inflammatory factor include TNF-α, interleukin 6（IL-6）, interleukin 12（IL-12） levels were observed in each group. Results： After treatment, NIHSS scores were significantly decreased compared with before treatment, and the observation group decreased more significantly than the control group, the difference was statistically significant（P〈0.05）; The total effective rate of observation group was 77.27%, significantly higher than 50.00% in control group,the difference was statistically significant（P〈0.05）, and there were no serious adverse events during treatment. After treatment, serum inflammatory factor levels were significantly reduced in the two groups, the difference was statistically significant（P〈0.05）, and the improvement degree of the observation group was significantly better than the control group, the difference was statistically significant（P〈0.05）. Conclusion： Edaravone combined with rt-PA can significantly reduce inflammation in patients with CI, improve the degree of neural function defect, it is worthy of clinical promotion.

关 键 词：依达拉奉 重组组织型纤溶酶原激活剂 脑梗死 炎症因子 

分 类 号：R743[医药卫生—神经病学与精神病学]